Selective ghrelin/GHSR-1a receptor agonist
PRODUCT PROFILE
Ipamorelin
Price range: £34.99 through £54.99
Ipamorelin is selective ghrelin/ghsr-1a receptor agonist. Researchers examine it in relation to pulsatile pituitary gh release through the ghrelin-receptor pathway.
Why it is distinct
A ghrelin-receptor secretagogue—not a GHRH analogue—and generally discussed as more selective than older GHRPs.
- Evidence stageEarly human evidence
- AvailabilityAvailable · 20 in stock
- Batch recordPublished after verification
- DispatchConfirmed at checkout
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Ipamorelin is selective ghrelin/ghsr-1a receptor agonist. Researchers examine it in relation to pulsatile pituitary gh release through the ghrelin-receptor pathway.
Research focus+
Researchers study whether it can trigger a focused pulse of growth hormone with fewer effects on other pituitary hormones than older compounds. Reliable long-term human evidence is limited.
How the mechanism differs+
Activates the growth-hormone secretagogue receptor rather than the GHRH receptor; early studies suggested relative GH selectivity.
Evidence and limitations+
Early human pharmacology exists, but there is no established authorised therapeutic indication and outcome evidence is limited.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study whether it can trigger a focused pulse of growth hormone with fewer effects on other pituitary hormones than older compounds. Reliable long-term human evidence is limited.
Activates the growth-hormone secretagogue receptor rather than the GHRH receptor; early studies suggested relative GH selectivity.
A ghrelin-receptor secretagogue—not a GHRH analogue—and generally discussed as more selective than older GHRPs.
Early human pharmacology exists, but there is no established authorised therapeutic indication and outcome evidence is limited.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability